Source
From SEC EDGAR
149 releases originally issued via SEC EDGAR. The issuing organizations are responsible for their content.
Xencor Reports Third Quarter 2026 Financial Results
-- Updated results for XmAb819 (ENPP3 x CD3) in advanced clear cell renal cell carcinoma and outline of plans for potential registration-enabling…
HOST HOTELS & RESORTS, INC.
Host Hotels & Resorts, Inc. Reports Results for the Third Quarter of 2026
Veracyte Announces Third Quarter 2026 Financial Results
Grew total revenue to $151.8 million and testing revenue to $146.4 million, representing 15% year-over-year growth
Excelerate Energy, Inc.
Excelerate Energy Reports Strong Third Quarter 2026 Results
CF Industries Holdings, Inc.
CF Industries Holdings, Inc. Reports First Nine Months 2026 Net Earnings of $1.78 Billion, Adjusted EBITDA of $3.01 Billion
Myriad Genetics Reports Third Quarter 2026 Financial Results;
Raises Mid-Point of Full-Year 2026 Revenue Guidance Following Solid Execution
Granite Point Mortgage Trust Inc. Reports
Third Quarter 2026 Financial Results
OPKO Health Reports Third Quarter 2026 Business Highlights and Financial Results
Conference Call to Begin Today at 4:30 p.m. ET
ORION S.A.
Aeva Reports Third Quarter 2026 Results
Expanded Product Portfolio in Optical Connectivity with Ultra-High Power Sources and Modules to Address Significant and Growing Demand for AI Data…
ZoomInfo Announces Third Quarter 2026 Financial Results
agilon health Reports Third Quarter 2026 Results
Revenue increased 6% to $1.52 billion Compared to the Same Period in the Prior Year
Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update
VAX-31 Adult Indication: Announced Positive Topline Data from OPUS-1 Pivotal Phase 3 Trial; VAX-31 Met All Prespecified Primary Endpoints, Was Well…
Kailera Reports Third Quarter 2026 Financial Results and Provides Business Updates
Ribupatide oral global Phase 3 program expected to begin in 1H 2027 following completion of End-of-Phase 2 meeting with FDA